IDH1 and astrocytoma (excluding glioblastoma): A peptide vaccine directed against IDH1 R132H was developed and tested in a Phase 1 trial, where it was given to patients with grade 3–4 astrocytoma either after radiotherapy or in conjunction with adjuvant temozolomide [41].